Patient-Reported Outcomes in Systemic Lupus Erythematosus

Overview

Journal Rheum Dis Clin North Am

Publisher Elsevier

Specialty Rheumatology

Date 2016 May 3

PMID 27133488

Citations 24

Authors

Mary Mahieu

Susan Yount

Rosalind Ramsey-Goldman

Affiliations

Soon will be listed here.

Abstract

Successful management of complex conditions such as systemic lupus erythematosus (SLE) and comorbid conditions benefit from patient-reported outcomes (PRO). Measuring health-related quality of life with PROs provides SLE patients with an opportunity to participate in their treatment and to facilitate better communication with the multidisciplinary team involved in their care. Health outcomes research has produced well-validated instruments that can be used across diseases; others have been specifically developed for SLE. The use of generic and SLE-specific PROs depends on needs, including population monitoring, treatment decision making, clinical trials research, and for evaluating and comparing the effect of therapies.

Citing Articles

Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study.

Sun K, Eudy A, Harris N, Pisetsky D, Criscione-Schreiber L, Sadun R J Patient Rep Outcomes. 2023; 7(1):136.

PMID: 38127169 PMC: 10739689. DOI: 10.1186/s41687-023-00678-5.

Circulating Mitochondrial DNA Is Associated With High Levels of Fatigue in Two Independent Sarcoidosis Cohorts.

Fiorini V, Hu B, Sun Y, Yu S, McGovern J, Gandhi S Chest. 2023; 165(5):1174-1185.

PMID: 37977267 PMC: 11110677. DOI: 10.1016/j.chest.2023.11.020.

Measuring What Matters: A Qualitative Study of the Relevance and Clinical Utility of PROMIS Surveys in Systemic Lupus Erythematosus.

Kasturi S, Ahearn E, Batterman A, Horton R, Kleinman J, Rose-Smith J J Rheumatol. 2023; .

PMID: 37399463 PMC: 10757986. DOI: 10.3899/jrheum.2023-0184.

Validation and the associated factors of the Malay version of systemic lupus erythematosus-specific health-related quality of life questionnaires (SLEQoL and LupusQoL).

Ahmad Pouzi N, Shaharir S, Mohd Tamil A, Mustafar R, Ahmad Maulana S, Mageswaren E PLoS One. 2023; 18(5):e0285461.

PMID: 37186611 PMC: 10184909. DOI: 10.1371/journal.pone.0285461.

Adaptation and validation of the Bulgarian version of the Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL).

Pencheva D, Coffey A, McKenna S, Monov S Clin Rheumatol. 2023; 42(7):1811-1817.

PMID: 36913029 DOI: 10.1007/s10067-023-06523-w.

References

Yen J, Neville C, Fortin P . Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials. Lupus. 1999; 8(8):660-70. DOI: 10.1191/096120399680411362. View

Neville C, Clarke A, Joseph L, Belisle P, Ferland D, Fortin P . Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. J Rheumatol. 2000; 27(3):675-9. View

Thumboo J, Fong K, Chan S, Leong K, Feng P, Thio S . A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol. 2000; 27(6):1414-20. View

Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P . Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus. 2000; 9(5):322-7. DOI: 10.1191/096120300678828424. View

Wang C, Mayo N, Fortin P . The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol. 2001; 28(3):525-32. View

Trager J, Ward M . Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001; 13(5):345-51. DOI: 10.1097/00002281-200109000-00002. View

Strand V, Aranow C, Cardiel M, Alarcon-Segovia D, Furie R, Sherrer Y . Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus. 2003; 12(9):677-86. DOI: 10.1191/0961203303lu440oa. View

Cervera R, Khamashta M, Font J, Sebastiani G, Gil A, Lavilla P . Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003; 82(5):299-308. DOI: 10.1097/01.md.0000091181.93122.55. View

Leong K, Kong K, Thong B, Koh E, Lian T, Teh C . Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford). 2005; 44(10):1267-76. DOI: 10.1093/rheumatology/keh605. View

10.

Ware Jr J, Sherbourne C . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30(6):473-83. View

11.

Bernatsky S, Boivin J, Joseph L, Manzi S, Ginzler E, Gladman D . Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006; 54(8):2550-7. DOI: 10.1002/art.21955. View

12.

McElhone K, Abbott J, Teh L . A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006; 15(10):633-43. DOI: 10.1177/0961203306071710. View

13.

Mcelhone K, Abbott J, Shelmerdine J, Bruce I, Ahmad Y, Gordon C . Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007; 57(6):972-9. DOI: 10.1002/art.22881. View

14.

Stamm T, Bauernfeind B, Coenen M, Feierl E, Mathis M, Stucki G . Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. Arthritis Rheum. 2007; 57(7):1287-95. DOI: 10.1002/art.23013. View

15.

Kuriya B, Gladman D, Ibanez D, Urowitz M . Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum. 2008; 59(2):181-5. DOI: 10.1002/art.23339. View

16.

Doward L, McKenna S, Whalley D, Tennant A, Griffiths B, Emery P . The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2008; 68(2):196-200. DOI: 10.1136/ard.2007.086009. View

17.

Mok C, Ho L, Cheung M, Yu K, To C . Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol. 2008; 38(2):121-7. DOI: 10.1080/03009740802415527. View

18.

Jolly M, Pickard A, Wilke C, Mikolaitis R, Teh L, McElhone K . Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann Rheum Dis. 2009; 69(1):29-33. DOI: 10.1136/ard.2008.094763. View

19.

Pons-Estel G, Alarcon G, Scofield L, Reinlib L, Cooper G . Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2009; 39(4):257-68. PMC: 2813992. DOI: 10.1016/j.semarthrit.2008.10.007. View

20.

Aggarwal R, Wilke C, Pickard A, Vats V, Mikolaitis R, Fogg L . Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol. 2009; 36(6):1209-16. DOI: 10.3899/jrheum.081022. View